[go: up one dir, main page]

AR052104A1 - Formas de dosificacion de inhibidores de la proteina de transferencia de esteres de colesterilo e inhibidores de la hmg- coa reductasa - Google Patents

Formas de dosificacion de inhibidores de la proteina de transferencia de esteres de colesterilo e inhibidores de la hmg- coa reductasa

Info

Publication number
AR052104A1
AR052104A1 ARP060100361A ARP060100361A AR052104A1 AR 052104 A1 AR052104 A1 AR 052104A1 AR P060100361 A ARP060100361 A AR P060100361A AR P060100361 A ARP060100361 A AR P060100361A AR 052104 A1 AR052104 A1 AR 052104A1
Authority
AR
Argentina
Prior art keywords
inhibitors
hmg
colesterilo
esteres
protein
Prior art date
Application number
ARP060100361A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AR052104A1 publication Critical patent/AR052104A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Una forma de dosificacion que incluye un inhibidor de la proteína de transferencia de ésteres de colesterilo en una forma de solubilidad mejorada y un inhibidor de la HMG-CoA reductasa, en la que la forma de dosificacion proporciona liberacion inmediata del inhibidor de la HMG-CoA reductasa y liberacion controlada y liberacion inmediata del inhibidor de la proteína de transferencia de ésteres de colesterilo.
ARP060100361A 2005-02-03 2006-02-01 Formas de dosificacion de inhibidores de la proteina de transferencia de esteres de colesterilo e inhibidores de la hmg- coa reductasa AR052104A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65004805P 2005-02-03 2005-02-03
US73922005P 2005-11-22 2005-11-22

Publications (1)

Publication Number Publication Date
AR052104A1 true AR052104A1 (es) 2007-02-28

Family

ID=36123425

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060100361A AR052104A1 (es) 2005-02-03 2006-02-01 Formas de dosificacion de inhibidores de la proteina de transferencia de esteres de colesterilo e inhibidores de la hmg- coa reductasa

Country Status (7)

Country Link
US (1) US20080145427A1 (es)
EP (1) EP1845953A1 (es)
JP (1) JP2006213713A (es)
AR (1) AR052104A1 (es)
CA (1) CA2601762A1 (es)
TW (1) TW200638950A (es)
WO (1) WO2006082500A1 (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006129167A1 (en) * 2005-05-31 2006-12-07 Pfizer Products Inc. PHARMACEUTICAL COMPOSITIONS OF CHOLESTERYL ESTER TRANSFER PROTEIN INHIBITORS AND HMG-CoA REDUCTASE INHIBITORS
WO2007014393A2 (en) 2005-07-28 2007-02-01 Isp Investments Inc. Amorphous efavirenz and the production thereof
WO2008105752A1 (en) * 2006-05-08 2008-09-04 Mcneil-Ppc, Inc. Osmotic dosage form
WO2008065504A1 (en) 2006-11-30 2008-06-05 Pfizer Products Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
US11116728B2 (en) * 2006-11-30 2021-09-14 Bend Research, Inc. Multiparticulates of spray-coated drug and polymer on a meltable core
US8613946B2 (en) 2006-12-21 2013-12-24 Isp Investment Inc. Carotenoids of enhanced bioavailability
US10189957B2 (en) 2007-01-26 2019-01-29 Isp Investments Llc Formulation process method to produce spray dried products
KR20100125346A (ko) 2008-02-27 2010-11-30 토멘 메디칼 아게 임플란트 및 이의 제조 방법
EP2348835A4 (en) 2008-09-28 2014-01-22 Knc Ner Acquisition Sub Inc MIXES FROM MULTICOLOR CATECHOL COMPOUNDS
AR075180A1 (es) * 2009-01-29 2011-03-16 Novartis Ag Formulaciones orales solidas de una pirido-pirimidinona
US8968456B2 (en) * 2009-08-28 2015-03-03 Hercules Incorporated Film coating composition from solid powder hydrophobic compounds
EP2314286A1 (de) * 2009-10-21 2011-04-27 Ratiopharm GmbH Schmelzgranuliertes Cinacalcet
KR20120068277A (ko) * 2010-12-17 2012-06-27 한미사이언스 주식회사 ＨＭＧ－ＣｏＡ 환원효소 억제제 및 아스피린을 포함하는 약제학적 복합제제
IN2012DE00826A (es) * 2012-03-21 2015-08-21 Ranbaxy Lab Ltd
CN102755322B (zh) * 2012-07-24 2013-12-11 兆科药业（广州）有限公司 一种乐卡地平和阿托伐他汀复方制剂
CN104069502B (zh) * 2013-03-29 2018-02-16 北京罗诺强施医药技术研发中心有限公司 复合骨架材料及其药物组合物
US20160183559A1 (en) * 2013-07-30 2016-06-30 Benemilk Oy Dietary compositions for ruminants and containers for storing and dispensing same
US20160183563A1 (en) * 2013-07-30 2016-06-30 Benemilk Oy Feed for lactating ruminants
ES2837149T3 (es) 2014-04-21 2021-06-29 Heron Therapeutics Inc Composiciones de un poliortoéster y un excipiente de ácido orgánico
JP2019131472A (ja) * 2016-05-31 2019-08-08 興和株式会社 医薬組成物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69324504T2 (de) * 1993-01-19 1999-08-26 Warner-Lambert Co. Stabilisierte, oral anzuwendende zusammensetzung enthaltend die verbindung ci-981 und verfahren
US20010006644A1 (en) * 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
DE60039802D1 (de) * 1999-02-10 2008-09-25 Pfizer Prod Inc Vorrichtung mit matrixgesteuerter Wirkstofffreisetzung
EP1027888B1 (en) * 1999-02-10 2009-06-10 Pfizer Products Inc. Osmotic system for delivery of solid amorphous dispersions of drugs
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
US20030086972A1 (en) * 2000-08-09 2003-05-08 Appel Leah E. Hydrogel-driven drug dosage form
CA2419406A1 (en) * 2000-08-15 2002-02-21 Pfizer Products Inc. Pharmaceutical combinations of torcetrapib and atorvastatin or hydroxy derivatives for the treatment of atherosclerosis, angina and low hdl levels
PL371416A1 (en) * 2002-02-01 2005-06-13 Pfizer Products Inc. Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
CA2534371A1 (en) * 2003-08-04 2005-02-10 Pfizer Products Inc. Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors

Also Published As

Publication number Publication date
EP1845953A1 (en) 2007-10-24
TW200638950A (en) 2006-11-16
JP2006213713A (ja) 2006-08-17
CA2601762A1 (en) 2006-08-10
US20080145427A1 (en) 2008-06-19
WO2006082500A1 (en) 2006-08-10

Similar Documents

Publication Publication Date Title
AR052104A1 (es) Formas de dosificacion de inhibidores de la proteina de transferencia de esteres de colesterilo e inhibidores de la hmg- coa reductasa
AR045203A1 (es) Formas de dosificacion de inhibidores de la proteina de transferencia de colesteril ester e inhibidores de la hmg-coa reductosa
DOP2019000185A (es) Una formulación sólida de dosificación farmacéutica
UY31897A1 (es) Combinación de metotrexato con inhibidores dhodh
CO6531429A2 (es) Inhibidores de la tirosina quinasa de bruton
GT200300023A (es) Formas de dosificacion farmaceutica de liberacion controlada de un inhibidor de la proteina de transferencia de ester de colesterilo
CY2016041I2 (el) Αναστολεις κινασης τυροσινης bruton
ECSP13012394A (es) Nuevas formas de dosificación de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidores de xantina oxidasa
JO3492B1 (ar) تركيبات صيدلانية من مضاد مستقبل أنجيوتنسين ومثبط nep
MX2014000518A (es) Inhibidores de la tirosina quinasa de bruton.
RS50621B2 (sr) Inhibitori dipeptidil peptidaze
PA8564901A1 (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo
MX2019005150A (es) Inhibidores de la tirosina-cinasa de bruton.
ECSP088440A (es) Imidazopirazinas como inhibidores de proteinquinasa
ECSP11011417A (es) Anticuerpos anti-fgfr3 y métodos que los utilizan
CL2010001426A1 (es) Compuestos derivados de triciclos, inhibidores de la proteina quinasa; composicion farmaceutica que los comprende; utiles en el tratamiento de enfermedades oncologicas e inmunologicas.
NO20081636L (no) FAP - inhibitorer
CL2010001483A1 (es) Compuestos derivados de 5-fenil-1h-piridin-2-ona y 6-fenil-2h-piridazin-3-ona, inhibidores de tirosina-quinasa (btk); composicion farmaceutica que comprende a dichos compuestos y su uso para el tratamiento de un estado patologico inflamatorio y/o autoinmune.
ZA200801592B (en) Novel pharmaceutical modified release dosage form cyclooxygenase enzyme inhibitor
CL2011002569A1 (es) Procedimiento de tratamiento o prevencion que comprende administrar un inhibidor de tirosina cinasa y un inhibidor de igf-1r.
EA200970164A1 (ru) Ингибиторы каспазы на основе пиридазинонового каркаса
CY1111768T1 (el) Νεος παραγοντας μειωσης τριγλυκεριδιου
CL2012001159A1 (es) Composicion que comprende un inhibidor de alfa-1-proteinasa (api), y como minimo, un aminoacido; kit que comprende dicha composicion que se utiliza como una composicion farmaceutica adecuada para administracion intravenosa.
CY1114113T1 (el) Συνδυασμος ενος αναστολεα του κολπικου ρευματος if και ενος βητα-αναστολεα
CL2012000350A1 (es) Combinacion farmaceutica que comprende un compuesto derivado de bifenilamida y un agente inhibidor de bcr-abl seleccionado de nilotinib; composicion farmaceutica; y uso de la combinacion para el tratamiento de leucemia positiva a bcr-abl.

Legal Events

Date Code Title Description
FB Suspension of granting procedure